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Abstract: To improve well-known titanium implants, pores can be used for increasing bone 
formation and close bone-implant interface. Selective Laser Melting (SLM) enables the 
production of any geometry and was used for implant production with 250-µm pore size. 
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The used pore size supports vessel ingrowth, as bone formation is strongly dependent on  
fast vascularization. Additionally, proangiogenic factors promote implant vascularization. To 
functionalize the titanium with proangiogenic factors, polycaprolactone (PCL) coating can 
be used. The following proangiogenic factors were examined: vascular endothelial growth 
factor (VEGF), high mobility group box 1 (HMGB1) and chemokine (C-X-C motif) ligand 
12 (CXCL12). As different surfaces lead to different cell reactions, titanium and PCL coating 
were compared. The growing into the porous titanium structure of primary osteoblasts  
was examined by cross sections. Primary osteoblasts seeded on the different surfaces were 
compared using Live Cell Imaging (LCI). Cross sections showed cells had proliferated, but 
not migrated after seven days. Although the cell count was lower on titanium PCL implants 
in LCI, the cell count and cell spreading area development showed promising results for 
titanium PCL implants. HMGB1 showed the highest migration capacity for stimulating the 
endothelial cell line. Future perspective would be the incorporation of HMGB1 into PCL 
polymer for the realization of a slow factor release. 
Keywords: titanium implant; selective laser melting; polycaprolactone; VEGF; HMGB1; 
CXCL12; cross section; live cell imaging; osteoblast; cell migration 
 
1. Introduction 
Titanium is well established as implant material and can be manufactured accurately via Selective 
Laser Melting (SLM). SLM-made titanium constructions are commercially generated for this purpose 
(e.g., SLM Solutions GmbH, Luebeck, Germany) and allow the production of nearly any geometry [1].  
In general, SLM can be described as wetting solidified material with liquid metal that is melted by laser 
radiation. Therefore, it is necessary that oxide layers are removed as they interfere with the wetting 
process [2]. Titanium is known for its large solubility for oxygen [3]. Therefore it has been suggested 
that oxides can be dissolved [4] and thus medical devices can be manufactured by SLM that provide an 
adequate surface quality [5]. Implant geometry is a key factor in bone modeling [6]. Especially porous 
implants support tight bone-implant interface. Different studies demonstrated an efficient bone ingrowth 
into porous titanium scaffolds [7,8], whereas the pore size examined for bone tissue engineering is very 
heterogeneous and varies from 20 to 1500 µm [9]. In general, porous titanium is well known as being 
stable and osteoconductive [8]. To achieve enhanced bone ingrowth, it is important that the cells are able 
to migrate into the structures of the porous implant. The cells that are located in the porous structure are 
in need of fast vascularization to achieve sufficient nutrition. Especially in large sized osseous defects, 
the early vascularization is prerequisite, as a long distance must be bridged for transporting nutrients, 
growth factors, and supporting gas exchange [10,11]. Geometry with 250 µm pore size is known to 
support angiogenesis [12]. 
Furthermore, improved vascularization can be approached by proangiogenic factors [13,14]. Using 
migration factors, survival of cells located in the scaffold can be improved. Vascular endothelial growth 
factor (VEGF) is well known as a proangiogenic factor, whereas high mobility group box 1 (HMGB1) 
has been discovered to also enhance angiogenesis [15,16]. Another factor that has been examined is 
Int. J. Mol. Sci. 2015, 16 7480 
 
 
chemokine (C-X-C motif) ligand 12 (CXCL12) in combination with HMGB1, where studies showed 
increasing chemotactic potency [17]. Achieving factor release, implant coating by biodegradable polymers 
with incorporated factors is common [18,19]. For this purpose, the polymer polycaprolactone (PCL)  
is applicable, as it is biocompatible, factors can be incorporated and it is already used for bone 
regeneration [20–22]. 
Herein, we ensured even PCL coating by Environmental Scanning Electron Microscopy (ESEM) and 
EDX measurements. In vitro results described an implant model based on an open porous titanium 
implant (later called titanium implant) in comparison with a PCL-coated titanium implant (later called 
titanium PCL implant). VEGF, HMGB1 and CXCL12 were examined using the endothelial cell line 
GM7373 in migration assays. To assess if cells are located in the porous structures of the implant, 
primary murine green fluorescent protein (GFP)-osteoblasts were seeded and examined by cross 
sections. Titanium implants and titanium PCL implants were compared using GFP–osteoblasts imaged 
in Live Cell Imaging (LCI). The cells were visualized directly on the implant surface to obtain a realistic 
interaction of cells with the implant material near to in vivo conditions. 
2. Results 
2.1. Manufacturing of Titanium Implants and Titanium Polycaprolactone (PCL) Implants 
Titanium implants produced by SLM had a pore and strut geometry of 250 µm and total dimensions 
of 3.5 mm width, 3.5 mm depth and 1.25 mm height. 
2.2. Characterization of PCL Coating on Porous Titanium Implants 
ESEM and EDX-measurements were performed to examine PCL coating on titanium implants. 
Surface coating of PCL coated implants could be visualized (Figure 1C,D). The atomic percentage of 
carbon and oxide determined by EDX measurements was clearly higher in coated implants in 
comparison to the non-coated titanium implants (Table 1). 
 
Figure 1. Representative Environmental Scanning Electron Microscopy (ESEM) micrographs 
of non-coated (A,B) and polycaprolactone (PCL)-coated (C,D) porous titanium scaffolds in 
overview and detail. 
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Table 1. Surface composition of titanium implants and titanium PCL implants analyzed by 
EDX measurement. The relevant elements titanium, carbon and oxygen (Ti, C and O) 
described in atomic percent (At-%) are listed. 
Scaffold Modification (At-%) Titanium Implant Titanium PCL Implant 
Ti 70.09 3.04 
C 4.68 74.87 
O 0.87 21.41 
2.3. Cross Sections Established of Titanium Implants 
Cross sections of the titanium implants (Figure 2) showed that the cell amount in both the upper and 
lower pores increased over time and showed a significant difference between days 1 and 7. (Figure 3A). No 
increase in cell distance from the starting point towards deeper parts occurred (Figure 3B). Additionally, 
the cell amount between the lower and upper pore was similar during the seven days. Statistical analysis 
was performed using the Global F-Test from the Analysis of Variance and Ryan–Einot–Gabriel–Welsh 
Multiple Range Test (p < 0.05). 
 
Figure 2. Cross section of titanium implant with green fluorescent protein (GFP)–osteoblasts 
settled for (A) one day; (B) three days; and (C) seven days. Cells were placed on the top of 
the implant (marked 0 µm). The distance between the horizontal lines is 100 µm. Pores are 
marked red and counted cells orange (Wimasis Image Analysis). 
 
Figure 3. Cont. 
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Figure 3. Cross sections were analyzed for changes in (A) total area of cell growth (µm2) 
and (B) growth distance (µm) of osteoblasts from top–bottom pores at different time points 
(day 1, day 3, day 7). Osteoblast growth area was significantly higher on day 7 in comparison 
with day 1, whereas osteoblast growth distance was nearly the same over the seven days. 
Statistical analysis was performed using the Global F-Test from the Analysis of Variance 
and Ryan–Einot–Gabriel–Welsh Multiple Range Test with n > 16 (* p < 0.05). 
2.4. Migration Assays of GM7373 on Vascular Endothelial Growth Factor (VEGF), High Mobility 
Group Box 1 (HMGB1), Chemokine (C-X-C Motif) Ligand 12 (CXCL12) 
The endothelial cell line showed the highest chemotaxis using HMGB1 (Figure 4). CXCL12 alone 
was less effective than VEGF. Combining a half a dose of HMGB1/CXCL12 and HMGB1/VEGF 
showed similar migration efficiency (Figure 4). To prove that CXCL12 supports migration in 
combination with HMGB1, additional assays were performed with different concentrations of HMGB1 
and CXCL12. HMGB1 in the highest concentration (150 ng/mL) together with CXCL12 (30 ng/mL) 
showed significantly higher chemotaxis for GM7373 compared to the other combinations of HMGB1 
and CXCL12. Two sample t-test was used as statistical test (p < 0.05). 
2.5. Live Cell Imaging (LCI) 
Fluorescent osteoblasts seeded on the implants were tracked (Figure 5), cell numbers counted and 
cell size examined. Regression analysis illustrated changes in the cell number and shape over time while 
the two sample t-test compares cells at every single time point. Tracking cell number changes over time 
showed no differences between the two regression curves of titanium implants and titanium PCL 
implants (Figure 6A). Total cell numbers were significantly higher on titanium implants in comparison 
with titanium PCL implants on days 2, 3, 4 and 7. The cell spreading area was significantly higher for 
titanium PCL implants on day 4 (Figure 6B). Regression curves were different for the cell spreading 
area at the two implants; the titanium PCL implant showed higher values. (Statistic used: comparison of 
the two regression coefficients using an analysis of covariance with a test of the interaction between the 
two implant materials and time with p < 0.05). 
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Figure 4. Comparison of chemotactic behavior of the endothelial cell line (GM7373)  
using vascular endothelial growth factor (VEGF), high mobility group box 1 (HMGB1), 
chemokine (C-X-C motif) ligand 12 (CXCL12) and combinations of HMGB1/CXCL12  
and HMGB1/VEGF. For migration assays the negative control was set one and the other 
factors are its multiple. HMGB1 was more chemotactic than VEGF. CXCL12 induced  
lower migration of endothelial cells. Both factor combinations showed similar chemotaxis. 
Statistical test is two sample t–test with n = 6 (* p < 0.05). 
 
Figure 5. Titanium implant (90 degree angle and visible pore structure) after (A) 0 days;  
(B) three days; and (C) seven days and titanium PCL implant (45 degree angle and invisible 
pore structure) after (D) 0 days; (E) three days; and (F) seven days of GFP–osteoblast 
settling. (Scale bar: 75 µm) 
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Figure 6. Evaluation of average GFP–osteoblast cell number changes (A) and cell spreading 
area (µm2/cell) changes (B) during seven days settled on titanium (the solid line represents 
the cell development on the titanium implant with the single time points: ○) and titanium 
PCL implants(the dotted line represents the cell development on the titanium PCL implant 
with the single time points: +). The statistical approach used is comparison of the two 
regression coefficients using an analysis of covariance with a test of the interaction between 
the two implant materials and time with n > 3 (p < 0.05). The regression curves showed no 
changes in the number of cells over seven days, however there was a difference in the cell 
spreading area. 
3. Discussion 
Implant failure addressing larger bone defects is often attributable to insufficient bone healing, mainly 
depending on insufficient vascularization. Bone replacement material should provide adequate 
mechanical properties being comparable to native bone in order to withstand the external forces. Aim of 
this study was to generate and evaluate a titanium implant structure characterized by a defined porous 
structure in order to provide a supportive feature facilitating vascularization. Additionally proangiogenic 
factors were analyzed to support a fast vessel ingrowth. As these factors can be integrated in PCL, PCL 
coating was evaluated. In order to generate these defined porous structures within the implants SLM was 
chosen as manufacturing option. In general, manufacturing of defined porous structures can be achieved 
by different rapid prototyping methods. Common manufacturing methods of porous titanium implants 
are SLM, Electron Beam Melting (EBM) and Laser Engineered Net Shaping (LENS) [23]. Raw material 
used within these methods is titanium powder and implants are manufactured with either laser beam 
(SLM and LENS) or electron beam (EBM) [24]. Murr et al. reported many advantages of SLM and EBM 
in contrast to conventional manufactured titanium implants, such as improved mechanical properties [25]. 
Both the SLM and LENS process achieved similar strength, surface roughness and accuracy [26]. 
Despite of the manufacturing method, all porous titanium implants showed good biocompatibility [27]. 
To ensure cells are able to seed in the inner pore regions osteoblasts were seeded on the titanium 
implant, as they are essential for bone modeling. In general imaging and thus tracking of cells in the 
porous implant structures is challenging as commonly the materials are not transparent impeding 
visualization based analyses. Consequently, commonly used employed cell counting assays cannot 
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detect cell location [28], while histology can determine cell count and location at once [29]. In this study 
fluorescent GFP–osteoblasts could be tracked in the porous structure analyzing cross sections. The cell 
surface area, which represents the number of cells, increased during the seven days of cell settling. The 
increased measured cell surface area is a value describing cell proliferation. Consequently, the results 
indicate that osteoblasts could proliferate into the pores. Furthermore, the proliferation effects are 
dependent on sufficient nutrition of the ingrowing cells. Thus the selected pore size allows sufficient 
media exchange to keep the cells vital. The chosen small pore size of 250 µm allowed high cell seeding 
inside the implant. An earlier study reported higher cell counts even for 500 µm pore size in comparison 
with 1000 µm pore size of SLM made titanium implants [6]. This difference in size effect was discussed 
to be associated to lower implant permeability allowing more cells to become attached, resulting in an 
increased surface area [6]. Hence, the small pore size is supposed to enhance cell attachment. The SLM 
process generates pores that are regularly manufactured, allowing cells to spread easily through the 
whole scaffold. In contrast, implants generated by powder metallurgy provide pores with irregular and 
undefined pore geometries. In such structures the cells are only able to seed on the implant surface when 
cultivated in a static medium system [29]. Larger scaffolds were herein not examined, thus it is not 
known how deep cells could be located in the scaffold. Despite the fact that the used cells were able to 
seed in the porous structures, a direct migration could not be observed. A more efficient cell seeding 
could be potentially achieved by using migration factors. In general, directed cell migration into the 
implant could lead to improved bone modeling [30]. 
Aiming at a perspective improved implant vascularization, different proangiogenic factors were 
evaluated. Large defects require large implant structures, accordingly fast vessel ingrowth is key to 
support osseogenesis [31]. In this study migration assays were performed using the endothelial cell line 
GM7373. Endothelial cells already showed potent chemotaxis response to HMGB1 in an earlier  
study [32]. In fact, HMGB1 was more effective concerning GM7373 migration efficiency than the “gold 
standard” reference factor VEGF [33]. The observed potent chemotactic effect of HMGB1 compared to 
VEGF is of major value, as VEGF is one of the most commonly used proangiogenic factors [34,35]. 
Consequently the next step would be the evaluation of migration assays with primary endothelial cells 
and further cell types that are commonly present in bone tissue such as osteoblasts. 
CXCL12 has recently been focused as a chemotactic migration factor. Combining HMGB1 and 
CXCL12 should lead to improved chemotaxis, as recent studies showed that the factors were highly 
linked concerning mesoangioblasts, monocytes, macrophages and fibroblasts [17,36,37]. Schiraldi et al. 
demonstrated that HMGB1 and CXCL12 bind as a heterocomplex to the CXCR4 receptor [37]. Until 
now, little has been known about migration of endothelial cells as respond to CXCL12 stimulation. 
Herein it was demonstrated that the combination of HMGB1 and CXCL12 showed the same chemotactic 
efficiency for GM7373 compared to a HMGB1 and VEGF combination. 
Chemotactic factors as the herein evaluated can be incorporated into polymers on surfaces of the 
implant material. Thereby a directed release over time can be achieved leading to an enhanced factor 
concentration into the area of interest [38,39]. EDX and ESEM analyses showed in this study complete 
surface covering of PCL on the coated titanium implants. Consequently, the herein employed dipping 
process is sufficient to achieve the desired titanium implant functionalization as the implant pores 
remained open after the coating. This is highly important to maintain the desired open porous structure 
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and to enable vessel and bone ingrowth. As well implant functionalization with factors in the inner pore 
structure could be enabled. 
However, polymer coating itself changes surface characteristics of the coated implant material and 
thus could result in different cell behavior. In order to evaluate a polymer induced effect of cellular 
seeding capacity surfaces with and without polymer coating were comparatively analyzed. LCI of  
both implant types allow the analyses of cellular parameters as morphology, cell count, and viability 
simultaneously. Thereby defined implant sections were settled with cells and observed during the seven 
days monitoring the cellular behavior on the examined surface (Supplementary Video S1 and S2). This 
methodical approach provides a unique possibility for examining cell behavior of opaque material. 
However, the commonly used assays for cell visualization on implant materials require the fixing of the 
cells prior to imaging, allowing only a single time point analyses without the possibility to monitor cell 
behavior over time [40,41]. The results herein showed that the total cell number was significantly higher 
on the titanium implant structures when compared to the titanium PCL implant. The observed lower  
cell numbers on titanium PCL implants could be lower due to the higher hydrophobic values of the  
PCL [42]. When cells settle for the first time, only few proteins attach themselves to the surface and thus 
fewer cells are able to attach themselves. After a while extracellular matrix (ECM) molecules can bind 
to the PCL and cells are able to attach equally well to the titanium implant [43]. 
These results suggests that titanium PCL implants are not suitable for osteoblasts, but in vivo studies 
already showed good properties for bone modeling [44]. When looking at the cell spreading area we do 
have good results for titanium PCL implant. Furthermore, the development of cell numbers over seven 
days is similar for both implants. These results show that cell counting of single time points can lead to 
different results. The cell spreading area and the development of cell numbers can be a helpful addition 
for cell evaluation on implants. 
HMGB1, showing highest chemotactic potential, incorporated in PCL for porous titanium implant 
coating could be used in future research. 
4. Experimental Section 
4.1. Manufacturing Titanium Implant 
For the titanium implant a TiAl6V4 titanium alloy was used. The implants were manufactured by 
SLM Solutions GmbH, Lübeck, Germany, with an SLM 280HL Selective Laser Melting system. 
Therefore a standard parameter set was taken using a laser power of 275 W, a scan speed of 805 W and 
a hatch distance of 120 µm for the core volume. The outer contour was produced using a laser power of 
100 W and a scan speed of 350 mm/s. 
4.2. Dip-Coating Process for Application of Polymeric Coatings to Porous Titanium Scaffolds 
For implant coating a manual dip-coating process was established. First titanium implants were 
washed in isopropanol. For each implant, 2 mL of polymer solution was filled in the dipping tanks. 
Concentration was 0.4% of PCL. After each dipping process intermediate drying for 10 min at  
23 ± 2 °C was performed. This was repeated six times. Finally the titanium PCL implants were dried in 
a vacuum at 40 °C for 24 h. 
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4.3. Scanning Electron Microscopy and EDX Measurements 
To examine complete surface covering of the polymer coating, environmental scanning electron 
microscopy (Quanta FEG 250, FEI, Eindhoven, The Netherlands) equipped with an energy-dispersive  
X-ray (EDX) analysis unit was used. After fixing the titanium PCL implants and the titanium implants, 
the scanning electron micrographs were performed at 50 Pa pressure, moisturized atmosphere and an 
accelerating voltage of 10 kV. EDX measurements were performed at the beam entrance of the electron 
microscope. Titanium and carbon were determined by analyzing the spectra of the fibers bombarded 
with electrons. 
4.4. Cell Culture 
4.4.1. Greenfluorescent Protein (GFP)–Osteoblast Isolation 
Cell isolation was performed using adult GFP*C57Bl6 mice as previously described [45]. After 
mincing the bone of the calvarias into small pieces, 200 U/mL collagenase II (Cell Systems, Troisdorf, 
Germany) in Hank’s medium (HBSS, PAA Laboratories GmbH, Pasching, Austria) was used. Five 
milliliters collagenase solution was used for calvarias of ten mice. Digestion took place five times for  
10 min at 37 °C. The supernatant of the final three steps was centrifuged (1200 rpm, 7 min). After 
washing the pellet twice with culture medium, cells were placed in culture plates and incubated at 37 °C. 
The medium used was DMEM (Biochrom AG, Berlin, Germany) with the addition of 10% fetal calf 
serum (FCS), 20 mM Hepes, 1000 IU/mL penicillin and 0.1 mg/mL streptomycin (all PAA, Coelbe, 
Germany). After cells had been isolated they were incubated at 37 °C with 8.5% CO2. Media changing 
was done every 3rd day until cells were confluent. For cell experiments cells were cultured in DMEM 
with 10% FCS and incubated at 37 °C with 5% CO2. 
4.4.2. GM7373 
The endothelial cell line GM7373 was harvested from the aorta of a bovine calf. For cell culture,  
we used DMEM and 10% FCS. GM7373 was provided by Leibniz University, Institution of Biophysics, 
Hannover, Germany. 
4.5. Cross Sections Established of Titanium Implants 
Nine titanium scaffolds were seeded with 2.5 × 104 GFP–osteoblasts (P 10). After one, three and 
seven days, three cell-seeded scaffolds each were fixed in 4% formalin. The samples were rinsed with 
tap water and dehydrated using an ethanol gradient (4 h in 70%, 80%, 90% and 100% ethanol). 
Afterwards, samples were defatted in acetone for 4 h, equilibrated with 100% ethanol for 6 h and 
embedded in methyl metacrylate for 2 days at 37 °C. Thirty-micrometer sections were cut with an 
internal hole saw (SP 1600, Leica, Wetzlar, Germany) and examined by fluorescence microscopy 
(DM4000B Leica microsystems, Wetzlar, Germany). Cell distance, cell amount, and difference in cell 
counting between upper and lower pores were examined by Wimasis Image Analysis (16–19 cross 
sections for each time point). The scale bar started at the scaffolds’ surface where cells had been settled 
and upper and lower pore were examined. Cells were counted as cell area, because after embedding the 
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cells were unable to be counted separately. Only cells that had direct contact to the pores surface were 
counted. Cells that were not attached to the surface were ignored because they could be artifacts of the 
cutting process. 
4.6. Migration Assays of GM7373 on HMGB1, VEGF, CXCL12 
Twelve-well transwells (353182, BD Falcon, Erembodegem, Belgium) with 8 µm pore-size were 
used for the experiment. Seventy thousand GM7373 of passages 20 and 21 were added to a 37 °C  
pre-warmed 0.1% DMEM and incubated for 20 min. The following factors were added in duplicate: 
VEGF (450-32, Peprotech, Hamburg, Germany) (5/10/20 ng/mL), HMGB1 (H4652, Sigma–Aldrich, 
Taufkirchen, Germany) (50/100/150 ng/mL), CXCL12 (250-20A, Peprotech) (50/100/150 ng/mL),  
and VEGF combined with HMGB1 and HMGB1 plus CXCL12 using half of the mentioned dose.  
After that in duplicate two assays were performed using HMGB1 (50/100/150 ng/mL) plus CXCL12 
(10/20/30 ng/mL) and HMGB1 (10/20/30 ng/mL) plus CXCL12 (50/100/150 ng/mL). Migration time 
was 4 h under cell culture conditions (37 °C, 5% CO2). Cells that did not migrate were removed with  
a cotton stick. Migrated cells in the lower chamber were trypsinated and counted with a cell counter 
(CellometerTM Auto 4, Nexcelom Bioscience, Lawrence, MA, USA). 
4.7. Live Cell Imaging 
LCI was performed with titanium implants and titanium PCL implants seeded with GFP–osteoblasts 
(LAS AF 2.6.0, Leica–Microsystems, Wetzlar, Germany). 
Four titanium implants and three titanium PCL implants were placed in a 96 well plate filled with 
150 µL DMEM and 10% FCS. GFP–osteoblasts (P 10) were added gently to the top of the scaffolds at 
a concentration of 2.5 × 104 cells/150 μL medium. After a minimum 5 h incubation period at 37 °C,  
5% CO2, the implants were turned upside down to visualize the cells in the inverse microscope. 
Subsequently, they were placed in new wells that were prepared with purpose-built Teflon constructs 
used for lifting the implants to create a gap between cells growing on the implants and the bottom of the 
culture plates for inverse microscopy. Then proliferation and motility of the cells could be observed  
by LCI Microscope (DMI 6000B Leica Microsystems, Wetzlar, Germany) during seven days with the 
program LAS AF 2.6.0. The same implant region was examined for seven days by taking pictures every 
15 min. A constant temperature of 37 °C was kept and a 5% CO2 was ensured by using a heating unit 
and CO2 supplier. Cells of the same concentration without scaffolds were used for positive control.  
Cell count and cell spreading area were examined by Wimasis Image Analysis GmbH, Germany.  
The cell spreading area of osteoblasts was described by using the following equation: total cell area/total 
cell number. 
4.8. Statistical Analysis 
Statistical analyses were performed with SAS® software, Version 9.3 (SAS Institute Inc., Cary,  
NC, USA). The significance level for all tests was set to p < 0.05. The data were shown as  
mean ± standard deviation. 
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5. Conclusions 
The SLM generated titanium implants with 250-µm pore size enabled osteoblast seeding and 
proliferation into the deeper pore areas. PCL coating lowered the amount of adhered cell in comparison 
to the non-coated titanium structure. However, the cell number development and cell spreading area was 
unhindered by the PCL coating. Furthermore, the PCL coating method maintained the open porous 
structures. Thus, PCL can be used for implant coating and factor incorporation in structures ranging 
around 250 µm. HMGB1 showed even higher chomotactic potential on endothelial cells compared to 
VEGF in vitro. PCL coated porous titanium implants functionalized with HMGB1 would be a potent 
combination for supporting angiogenesis in bony defects. 
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